Serbia expands drug reimbursement list, cuts co-payments for 769 medicines and moves ahead with tax reforms

The Serbian cabinet approved a new regulation expanding the list of medicines covered by compulsory health insurance. The update adds 145 prescription drugs, including innovative therapies for rare, oncological and cardiovascular diseases, and introduces numerous generic products to increase market competition. Patient co‑payment is reduced for 769 drugs previously on List A1, lowering out‑of‑pocket costs for many therapies.

At the same time, the government adopted proposals to amend several fiscal and regulatory laws: revisions to the Social Security Contributions Act, personal‑income‑tax law, corporate‑profit‑tax law and the Tobacco Act. These changes aim to align Serbia’s tax and regulatory framework with European Union standards as part of its EU accession agenda. An additional environmental protection strategy for the period up to 2033 was also endorsed.